Study Finds “High” Levels of Toxics in Top Makeup Products

New research is shining light on the ugly side of the cosmetics industry. A peer-reviewed study published last month in Environmental Science and Technology presented evidence that hundreds of makeup products contain “high” levels of organic fluorine. This is an indicator that they also contain per- and polyfluoroalkyl substances (PFAS), which are known more colloquially

Alzheimer disease treatment

Link confirmed between Alzheimer’s disease and gut microbiota

Swiss and Italian scientists have been able to prove a correlation between gut microbiota and the appearance of amyloid plaques in the brain, buildups typically associated with Alzheimer’s disease. Alzheimer’s disease is the most common cause of dementia and is an incurable condition that directly affects millions of people, and indirectly affects many more family

Research Study: COVID-19 lockdowns led to 95K fewer air pollution-related deaths globally

New research suggests that COVID-19 lockdowns led to 95,000 fewer air pollution-related deaths globally. Business closures and stay-at-home orders were the main drivers behind up to a 50% reduction in airborne concentrations of nitrogen dioxide, a direct emission from vehicles and coal-powered electricity plants. The greatest reduction in microscopic particulate matter released into the air

Vir and GSK Break Ground in COVID-19 Treatment Study

UPDATE 28/10/2021 Dr. Gupta’s work as lead researcher on this study has been published in The New England Journal of Medicine, in an article titled Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. You can find a link to the article on The Journal‘s website, here: https://www.nejm.org/doi/full/10.1056/NEJMoa2107934?query=featured_home UPDATE 30/8/2021 Dr. Gupta has given two

FDA Guidelines for Conducting Clinical Trials During COVID-19 Pandemic

The Food and Drug Administration (FDA) of the United States of America has recently issued a statement, updating Research Sites, Investigators, and IRBs on how best to deal with the ongoing challenges posed by COVID-19. These guidelines will help ensure the safety of trial participants, compliance with good clinical practice (GCP), and minimizing risks to